HYTRIN
LOE ApproachingNDAORALTABLET
Approved
Aug 1987
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
2/8 — Basic
Drug data last refreshed 4h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HYTRIN is an oral small-molecule tablet approved in 1987 by Abbott. The specific indication and mechanism of action are not documented in available data. The product is approaching loss of exclusivity and operates in a moderately competitive market segment.
LOE Approaching
Product is in late-stage lifecycle with moderate competitive pressure (30/100), suggesting potential team restructuring or transition planning within the next 2-3 years.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
FLOMAX® Versus HYTRIN® in Patients With the Signs and Symptoms of Benign Prostatic Hyperplasia
Started Aug 1998
1,993 enrolled
Prostatic Hyperplasia
Career Relevance
Zero linked job openings indicate this product is not actively hiring, consistent with its LOE-approaching lifecycle stage. Career opportunities are limited to retention roles managing market decline rather than growth expansion.
Brand Manager
Worked on HYTRIN at Abbott? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.